Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02157948 · ClinicalTrials.gov registry record · Phase 3
A Double-blind Study to Assess the Efficacy and Safety of Denosumab Produced by Two Different Processes in Postmenopausal Women With Osteoporosis
A Phase 3 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 394
- Enrollment target
NCT02157948 is a Phase 3 study that has completed, run by Amgen. The registered enrollment target is 394 participants.
The verdict
NCT02157948, a Phase 3 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 394 participants
- Enrollment target
Study Summary
This study will compare the effect of denosumab produced by two different manufacturing processes on bone mineral density at the lumbar spine in postmenopausal women with osteoporosis.
Interventions
- DRUG Denosumab (CP2)
- DRUG Denosumab (CP4)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 394 participants |
| Start Date | 2014-05 |
| Est. Completion | 2015-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02157948
The ClinicalTrials.gov registry entry for NCT02157948 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 394 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Denosumab (CP2) is the first listed.
NCT02157948 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02157948 about?
NCT02157948 is a clinical study titled "A Double-blind Study to Assess the Efficacy and Safety of Denosumab Produced by Two Different Processes in Postmenopausal Women With Osteoporosis". This study will compare the effect of denosumab produced by two different manufacturing processes on bone mineral density at the lumbar spine in postmenopausal women with osteoporosis.
What is the current status of trial NCT02157948?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 394 participants. The study started on 2014-05. Estimated completion is 2015-07.
What interventions are being tested in trial NCT02157948?
The interventions under investigation include: Denosumab (CP2) (DRUG), Denosumab (CP4) (DRUG).
Who is sponsoring clinical trial NCT02157948?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.